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A b s T r A C T
Autoimmune diseases such as rheumatoid arthritis 
(rA) result from a deregulation of immune responses 
culminating in immune-mediated tissue injury. in rA, this 
tissue injury is mainly reflected by synovitis and subsequent 
joint damage, although involvement of visceral organs 
(heart, lungs and kidneys) often leads to severe comorbidity. 
Accumulating evidence points towards dendritic cells 
(dC) as the principal regulators of the balance between 
immunity and tolerance. recently, a large body of evidence 
has demonstrated that the balance between activating 
and inhibitory fc gamma receptor (fcgr) subtypes is 
intricately involved in the regulation of dC behaviour. 
in this overview we summarise recent findings from 
our group and others that suggest an important role 
for fcgr in arthritis. furthermore, we postulate novel 
mechanisms of how triggering of fcgr might be used 
to manipulate dC function and combat autoimmunity. 
when dC are envisaged as useful targets in the light 
of dC immunotherapy in rA, detailed knowledge on 
the regulatory pathways of fcgr in rA is of paramount 
importance.
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i N T r o d u C T i o N
Dendritic cells (DC) represent a unique set of antigen-
presenting cells unrivalled in their capacity to attract and 
activate naive T cells and are therefore considered the most 
influential cells in the regulation of the immune response 
and the orchestration of tolerance.1 How DC fulfil these 
opposing tasks is potentially hidden in the fact that many 
features of DC are divided in time and place and translated 
into two developmental stages, namely immature and 
mature DC.2,3 Immature DC (iDC) are present in virtually 
all tissues where they encounter both self and non-self 
antigens. Triggered by a multitude of signals including 
selected pathogens and proinflammatory mediators, iDC 
mature after which they display an extraordinary immune-
stimulatory capacity. Compared with iDC, mDC express 
high levels of co-stimulatory and MHC molecules, de novo 
expression of maturation markers such as DC-LAMP 
and CD83 and low levels of receptors involved in antigen 
capture. This phenotype makes mDC perfectly adept for 
the presentation of antigens to neighbouring T cells that 
were captured beforehand.2,4,5 
Autoimmune diseases, such as RA, develop as a result 
of a loss of immune tolerance culminating in immune-
mediated tissue injury. Since DC are believed to be 
key regulators in directing the fine balance between 
tolerance and immunity, a major goal in the treatment of 
autoimmune diseases could be to deflect the presentation 
of self-antigens by DC to T cells so that anergic T cells or 
regulatory T cells are induced, thereby inducing torlerance.1,6,8 
Nowadays, an important role has been suggested for 
DC in synovial inflammation, supporting the theory 
that targeting DC is likely to be beneficial in RA.9-13 
However, tuning DC function as a therapeutic target in 
RA has not been tested thus far. In contrast, alteration 
of DC function has been exploited in other pathological 
conditions including cancer and transplantation medicine 
and holds great promise as a future therapy.14 In the battle 
against cancer, DC cultured with a proinflammatory 
phenotype and loaded with antigenic cargo originating 
from the tumour are generated and administered to 
patients eliciting antitumour responses. It is reasonable to 
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postulate that the potency of these ‘DC vaccine therapies’ 
might be extrapolated to create tolerogenic DC in case of 
autoimmunity and transplantation medicine, providing 
an attractive strategy to break the vicious circle of chronic 
inflammatory responses in autoimmune diseases such as 
RA. 
For the recognition and processing of antigens and 
subsequent activation, iDC are equipped with several 
mechanisms of which receptor-mediated endocytosis is 
considered the most important. Various receptors mediate 
antigen uptake; the Fc gamma receptors (FcgR) form the 
basis of this review. FcgR constitute a group of receptors 
designed to recognise IgG immunoglobulins or IgG-
containing immune complexes (IC) and are abundantly 
present in serum and synovial fluid of patients with 
rheumatoid arthritis (RA). In humans three classes can 
be distinguished, FcgRI, FcgRII and FcgRIII.15,16 FcgRII 
is further divided into two subtypes: FcgRIIa and FcgRIIb. 
FcgRIIa, together with FcgRI and III, activate cellular 
responses upon triggering, whereas FcgRIIb is a unique 
inhibitory FcgR.17,18 Since both activating and inhibitory 
FcgR are expressed on various immune cells, the concerted 
action of these opposing signalling systems unequivocally 
determines the cellular response.19 In accordance with this, 
it has been clearly shown that the determination of DC 
phenotype and behaviour is critically determined by FcgR 
triggering through IC, stressing the involvement of FcgR 
in both autoimmunity as well as tumour immunity.19-21 This 
review will mainly focus on the involvement of monocyte-
derived DC (moDC), and their surface FcgR, in the 
pathogenesis of RA. In addition we will elaborate on the 
potential of moDC and FcgR as promising therapeutical 
targets in the treatment of RA.
 
A r E  d C  i M p l i C A T E d  i N  s y N o v i A l 
i N f l A M M A T i o N ?
Many reports demonstrate the presence of DC in inflamed 
synovial tissue suggesting a critical role in RA. Recently, 
Weyand and colleagues categorised synovial inflammation 
into three main groups based on the appearance of DC and 
their location in secondary lymphoid organs.22 Remarkably, 
also fully matured DC are present in perivascular regions 
and ectopic lymphoid organs in synovial tissue of RA 
patients, which is highly suggestive of an altered maturation 
process during synovitis.11,22-24 Highly interesting was the 
finding that synovial DC in RA reflect characteristics of 
cell activation such as increased expression of inducible 
heat-shock protein 70,25 presentation of specific immune-
epitopes,23 RANK-RANKL interactions which mirror DC-
T cell interaction in the target organ and the expression 
of transcription factors such as Jak3, STAT1, STAT4 and 
STAT6.11,26 Interestingly, alterations in DC phenotype 
and behaviour are not confined to the synovium in RA. 
In fact, our group has demonstrated that moDC obtained 
from circulating peripheral blood mononuclear cells 
displayed an increased expression of FcgRII.12 Further 
research has led to the observation that this increased 
expression of FcgRII resulted in an altered production 
of pro- and anti-inflammatory mediators (TNF-a, IL-6 
and chemokines) upon triggering by immune complexes 
(IC).27,28 In addition, moDC from RA patients were found 
to express high levels of Toll-like receptors (TLR) and were 
found to react more strongly upon TLR ligand stimulation 
than those from healthy controls. This suggests active 
involvement of moDC in the inflammatory process.29 
TLR are pattern recognition receptors that bind bacterial 
fragments and viral RNA (exogenous proteins) on the one 
hand, but on the other hand also ‘endogenous ligands’ 
including heat-shock proteins and cartilage degradation 
products.30 Since TLR triggering provides a very potent 
stimulus for immune activation of DC, the finding that 
TLR signalling is likely to occur in RA suggests a critical 
role for moDC during this condition. 
More evidence for the involvement of DC in synovitis 
originates from an elegant study from Leung et al. which 
demonstrates that DC primed with collagen are able to 
induce inflammatory arthritis after transfer.9 In line with 
this finding, DC that were genetically modified to express 
the anti-inflammatory cytokine IL-4 were capable of fully 
inhibiting collagen-induced arthritis.31,32 Since IL-4 is 
known to be a modulator of FcgR balance, this latter effect 
might be partially explained by the alteration of FcgR 
expression locally due to the presence of IL-4 producing 
cells. Likewise, IL-10-treated DC and exosomes derived 
from these DC were able to completely block the onset of 
a collagen-induced arthritis and even reduce the severity 
of an established arthritis.33 Altogether, these data clearly 
indicate that DC are involved in the onset and perpetuation 
of the inflammatory circle of synovitis and suggest that DC 
targeting is a challenging approach to treat rheumatoid 
arthritis.
T h E  r o l E  o f  f c gr  i N  A r T h r i T i s
The use of experimental arthritis models combined with 
the availability of FcgR knockout mice has lead to the 
appreciation of the role of FcgR in arthritis. For example, 
during antigen-induced arthritis and immune complex 
mediated arthritis the presence of activating FcgR (FcgRI 
and FcgRIII, mice lack FcgRIIa) was associated with 
chondrocyte death and cartilage erosion.34-37 Further 
investigation of the FcgR subtypes revealed that the 
expression of FcgRIII was required for the development of 
collagen-induced arthritis since FcgRIII -/- mice developed 
virtually no inflammatory signs and subsequent cartilage 
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damage.38 The absence of the inhibitory FcgR subtype 
IIb, on the other hand, renders mice susceptible to 
collagen-induced arthritis.39 In addition, it was recently 
hypothesised that FcgRIIb reduces both joint inflammation 
and destruction by inhibition of the activating FcgR and 
by the efficient clearance of immune complexes.40 An 
important role for the inhibitory FcgRIIb in arthritis was 
further substantiated by the finding that arthritis can be 
induced by a single injection of IgG anti-collagen type II 
antibody in mice lacking this receptor.41 In addition, it was 
observed that IL-13 mediated upregulation of FcgRIIb prior 
to immune-complex arthritis inhibited chrondrocyte death 
and cartilage matrix degradation, two key features of joint 
damage.42 
The role for FcgR in synovial inflammation in humans is 
less clear, but accumulating evidence suggests that these 
receptors are of considerable importance. Until recently a 
major problem in the study of FcgR on human myeloid cells 
was the inability to distinguish FcgRII subtypes (FcgRIIa 
and FcgRIIb) on the cellular surface. In the synovial 
tissue macrophages and DC are abundantly present and 
it was demonstrated that these cells express significantly 
higher levels of FcgRII and III when compared with those 
present in synovium from healthy controls.12,43 Similarly, 
it was found that moDC obtained from patients with RA 
express FcgRII at significantly higher levels than those 
from their healthy counterparts.12 Since these DC display 
an anti-inflammatory phenotype upon IC stimulation the 
increased expression of FcgRII was thought to reflect an 
increase in FcgRIIb. Intriguingly, this increased expression 
of FcgRII was unique for patients with active RA and still 
present after full maturation, suggesting that local factors 
responsible for this phenomenon are present during early 
moDC life as suggested previously.44 With the recent 
development of a unique antibody directed specifically 
against the inhibitory FcgRIIb (gifted by MacroGenics. 
Inc), it could be demonstrated that the inhibitory FcgRIIb 
subtype was largely responsible for the increased expression 
of FcgRII as observed before (manuscript in preparation). 
This is conform the hypothesis that FcgRIIb is pivotal 
in the counter-regulatory response of proinflammatory 
responses in RA. It was highly interesting to see that the 
functional polymorphism of the FcgRIIb (I232T) was 
identified as the strongest prognostic factor for radiological 
joint damage in RA and was found to modulate moDC 
function, further substantiating the important role of 
FcgR in RA.45 
A r E  d C  A N d  f c gr  C o N N E C T E d  i N  r A 
p A T h o l o g y ?
In order to prevent chronic inflammation and subsequent 
tissue damage, in time every established immune response 
has to be terminated. To this end, the immune system 
is provided with a multitude of inhibitory receptors 
that counteract the immune response.46 The inhibitory 
FcgRIIb is a perfect example of such. As discussed before, 
the expression of FcgRIIb on moDC from RA patients 
is found to be increased compared with those from 
healthy controls. Intriguingly, this increased expression 
was exclusively found in patients with an active phase 
of disease. Therefore, we postulated that FcgRIIb might 
function as a counteractive mechanism to dampen 
proinflammatory responses. During inflammation both 
pro- and anti-inflammatory cytokines are generated that 
regulate the balance between activating and inhibitory 
receptors, including FcgR. TNF-a and IFN-g are known 
to induce the upregulation of mainly activating FcgR 
whereas IL-4 and IL-13 were recently identified as factors 
that induce the opposite.19,47-49 Bearing these data in 
mind a conceptual framework can be envisaged in which 
proinflammatory cytokines will upregulate activating 
FcgR during the early stages of inflammation. Circulating 
immune complexes CIC, which are omnipresent in RA, 
will potentate the proinflammatory reaction by inducing 
cytokine production and moDC maturation. To counteract 
this initial proinflammatory response, anti-inflammatory 
cytokines will be produced through which inhibitory FcgR 
gain the upper hand, the IC will then provide a negative 
feedback loop silencing the inflammatory response. In 
line with this conceptual framework, IL-13 was found to 
be increased in both serum and synovial fluid from RA 
patients further supporting this hypothesis. 
Why then do RA patients develop chronic disease? 
Our previous findings along with the observations that 
intravenously administered immune globulins (IVIG) 
lack clinical efficacy in RA patients despite their success 
in many other inflammatory conditions including 
inflammatory myositis, Guillain Barré syndrome and 
multiple sclerosis, prompted us to hypothesise that the 
FcgRIIb pathway is defective in RA.50-54 The finding that 
IL-13-mediated upregulation of FcgRIIb is absent in RA 
strongly supports this hypothesis and warrants further 
research. 
C A N  f c gr s  b E  u s E d  A s  T h E r A p E u T i C 
T A r g E T s  i N  r A ?
Triggering of Toll-like receptors (TLR) provides a strong 
stimulus for DC activation. The notion that TLR are 
involved in the regulation of both innate and adaptive 
immune responses sparked a revolution of research 
in the potential role of these receptors in a plethora of 
inflammatory conditions. In RA, the role of TLR in 
the disease pathogenesis has only recently become a 
subject of intense investigation. Recent research has 
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demonstrated that TLR are expressed at increased levels 
in RA synovium,29,55 moDC from RA patients reacted more 
potently with TLR agonists compared with DC from healthy 
controls, producing vast amounts of proinflammatory 
cytokines,29 and RA synovial fibroblasts are activated by 
RNA released from necrotic cells.56 All these data suggest 
that a role for TLR in RA is likely. Recent observations 
suggesting an interaction between the inhibitory FcgRIIb 
and TLR4 are therefore intriguing since this might 
provide new insights in how to modulate TLR responses 
in vivo.49 It is tempting to speculate that local moDC 
might act as a counter-regulatory mechanism with the 
purpose to silence the inflammatory response and restore 
tolerance after eradication of the provocative element. 
DC fulfil a central role in the organisation of immune 
responses against pathogenic invaders and in preventing 
autoimmune responses harmful to the host. Their directive 
task in shaping the immune response makes DC excellent 
targets in the battle against rheumatoid arthritis and 
other autoimmune diseases. To suppress (auto)immune 
responses several potential strategies can be envisaged in 
which active modulation of DC function plays a prominent 
part. One approach would be aimed at stimulating the 
tolerogenic capacities of DC in vivo, preferably at the site 
of inflammation. Current research is now focussing on 
whether the inhibitory FcgRIIb could be targeted for this 
goal.
Although still little is known regarding the signals that 
can induce the tolerogenic pathway in DC, accumulating 
evidence indicates that various immunosuppressive 
pharmacological substances are able to modulate DC 
phenotype and function and it is conceivable that some 
might shift the balance between immunity and tolerance 
by interfering in DC pathways.57 Another strategy for 
the use of DC to combat autoimmune diseases might 
be to manipulate DC ex vivo, delivering ‘programmed 
DC’. By means of in-vitro culture strategies (Vit-D3 or 
dexamethasone or IL-10) or genetic modification the 
DC’s tolerogenic immune suppressive programme can be 
instigated. The potential effectiveness of such strategies 
has already been demonstrated in transplantation 
models in which moDC differentiated in the presence 
of vasoactive intestinal peptide, a known immunosup-
pressive neuropeptide, expressed an immune regulatory 
phenotype able to prevent acute graft-versus-host disease 
in vivo.58 In addition, DC genetically modified to express 
IL-4 were able to abrogate synovial inflammation and 
abolish subsequent cartilage damage in experimental 
arthritis models.32 Another possible way by which DC 
characteristics can be manipulated lies with the Toll-
like receptors. Repetitive triggering of DC via TLR was 
shown to abrogate their proinflammatory capacity whereas 
combinations of TLR were found to unleash a synergistic 
effect on DC with respect to DC activation.29,59,60 This 
suggests that stimulation of TLR, the selective blocking 
of TLR or the modulation of TLR responses might be 
used to modulate DC behaviour in such a manner that 
is favourable for the host. The use of such TLR-activated 
DC has shown promising results in the battle against 
melanoma.61,62 In the case of autoimmune diseases the 
inhibitory FcgRIIb might prove to be a valid target since 
this inhibitory receptor seems interconnected with TLR 
signalling and is known to be important in the delicate 
balance between tolerance and autoimmunity.49,63 
f u T u r E  p r o s p E C T i v E
Both DC and FcgR are implicated in the inflammatory 
pathways during synovitis in RA. The modulation of 
the balance between activating and inhibiting FcgR 
might provide a means to modulate the behaviour of DC. 
However, the upregulation and/or function of FcgRIIb 
seems to be defective in RA; further studies resolving the 
cause of this potentially altered FcgRII regulation pathway 
are currently being conducted. For a better understanding 
of DC biology in autoimmune diseases, more knowledge 
on this inhibitory pathway is warranted and might provide 
new clues regarding potential new treatment strategies to 
battle autoimmune diseases including RA. 
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